Inflammatory biomarkers in Alzheimer's disease plasma

NIMA Consortium; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease; Morgan, Angharad R.; Touchard, Samuel; Leckey, Claire; O'Hagan, Caroline; Nevado-Holgado, Alejo J.; Barkhof, Frederik; Bertram, Lars; Blin, Olivier

Published in:
Alzheimer's and Dementia

DOI:
10.1016/j.jalz.2019.03.007

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 09-11-2019
Featured Article

Inflammatory biomarkers in Alzheimer’s disease plasma


*Systems Immunity Research Institute and UK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, UK
bDepartment of Psychiatry, University of Oxford, Oxford, UK
cDepartment of Radiology and Nuclear Medicine, VU University Medical, Amsterdam, the Netherlands
dUCL Institutes of Neurology and Healthcare Engineering, University College London, London, UK
fMax Planck Institute for Molecular Genetics, Berlin, Germany
gAix-Marseille University, APHM, Institute Neurosciences, Pharmacology, Marseille, France
hMax Planck Institute for Molecular Genetics, Berlin, Germany
iUniversity of Geneva, Geneva, Switzerland
jReference Center for Biological Markers of Dementia, Institute Born-Bunge, Antwerp, Belgium
kIRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
lUniversity of Geneva, Geneva, Switzerland
mDepartment of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit, University of Heidelberg, Mannheim, Germany
nDivision of Clinical Geriatrics, Department of Neurobiology, Karolinska Institutet, Stockholm, Sweden
oDepartment of Old Age Psychiatry & Psychotic Disorders, Medical University of Lodz, Lodz, Poland
pSchool of Public Health, Imperial College London, London, UK
qDepartment of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
rSchool of Public Health, Imperial College London, London, UK
sCITA-Alzheimer Foundation, San Sebastian, Spain

B.P.M. is a consultant for GlaxoSmithKline (GSK), Roche, Alexion, and Achillion. F.B. is supported by the NIHR UCLH biomedical research center. S.E. reports research funding from Janssen Pharmaceutica N.V. and ADx Neurosciences (paid to institution). L.F. has received honoraria for consulting or educational lectures, and/or advisory boards from Allergan, Eli Lilly, Avraham Pharma, Axon Neuroscience, Axovant, Biogen, Boehringer Ingelheim, Eisai, Functional Neuronmodulation, H. Lundbeck A/S, Merck Sharp & Dohme, Novartis, Pfizer, Piramal Imaging, Pharmatropix, Pharmnext, Roche, and Willmar Schwabe. P.-L. has received honoraria for lecturing from Lilly, Nutricia, Stada, Schwabbe, General-Electric, and for participating in advisory boards from Biogen, Nutricia, Lilly, General-Electric. J.P. received grants from the Swiss National Science Foundation (SNF 320030L_141179), Fujirebio Europe, Lilly, Ono Pharma, and the Nestlé Institute of Health Sciences. J.R. was a full-time employee of GSK and is a GSK share holder. P.S. has acquired grant support (for the institution) from Piramal. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche (Diagnostics). He is PI of studies with Probiodrug and EIP Pharma. S.V. receives research support from the Memorabel program of ZonMw (the Netherlands Organization for Health Research and Development), Janssen Pharmaceutica N.V., and the Alzheimer’s Association.

*See Annex.

https://doi.org/10.1016/j.jalz.2019.03.007
1552-5260 © 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

Alzheimer’s disease (AD) is a complex neurodegenerative disorder that develops gradually and progressively, with symptoms progressing over time from mild forgetfulness to severe mental impairment. Early diagnosis is an essential requirement for effective intervention but is challenging because of current reliance on clinical observation and cognitive testing, with diagnosis confirmed postmortem by demonstrating typical AD brain pathology. Biomarkers of early disease might address this challenge and are thus an urgent unmet need.

Currently, cerebrospinal fluid (CSF) levels of amyloid β (Aβ) fragments and hyperphosphorylated or total tau are the most widely used biomarkers for AD [1, 2]; however, diagnostic accuracy varies between centers [3]. Furthermore, lumbar puncture is invasive and difficult to implement in the presymptomatic elderly population. The accessibility and practicability of obtaining peripheral blood to measure disease biomarkers make this an attractive option for early diagnosis and large-scale screening. Numerous discovery studies for blood-based biomarkers of AD have been reported, but validation and replication remain key challenges and none has yet achieved clinical usefulness [4–7]. Promising candidates do exist, for example, plasma Aβ42/40 ratio and neurofilament light chain [8], but more work is needed.

Considerable evidence implicates inflammation and complement dysregulation in AD pathogenesis. Genome-wide association studies demonstrated strong associations between AD and common SNPs in the gene encoding the complement regulator clusterin (CLU) [9]. A second genome-wide association study replicated the CLU association and identified association with an SNP in the CRI gene, encoding complement receptor 1 (CR1) [10]. These findings have been robustly replicated in diverse cohorts.
 Furthermore, pathway analysis has highlighted immunity, inflammation, and complement as key pathways in AD [11–13]. Other evidence implicating inflammation and complement includes longitudinal studies demonstrating that inflammation occurs years before AD onset [14,15], and cross-sectional studies reporting increased inflammatory markers in early AD [16]. Plasma markers of inflammation and complement dysregulation may therefore be useful biomarkers of early AD. Indeed, complement proteins, regulators, and activation products were altered in AD plasma and/or CSF [17], and in a systematic review of 21 discovery or panel-based blood proteomic studies, complement was the top implicated pathway across the studies [18].

The underpinning hypothesis of this study is that plasma levels of complement proteins and other inflammatory biomarkers differ between neurologically normal elderly controls (CTL) and those with mild cognitive impairment (MCI) and/or AD, between subjects with MCI and those with AD, and between subjects with MCI destined to rapidly progress to AD (progressors) and those who will not progress (nonprogressors). If proven, then the most informative of these plasma biomarkers can be used to diagnose, stratify, predict disease progression, and/or demonstrate response to intervention in MCI and AD. Analytes were selected based on biological evidence and published studies of inflammatory/complement biomarkers in neurodegeneration. In the discovery phase, we used singleplex and multiplex solid-phase enzyme immunoassays to measure 53 proteins comprising complement components, activation products and regulators, cytokines and chemokines in a large cohort comprising AD, MCI, and CTL samples. Proteins demonstrating association with AD and/or MCI in this discovery sample set were investigated further in two independent replication cohorts.

2. Methods

2.1. Study population

Discovery phase samples were from AddNeuroMed, a cross-European cohort for biomarker discovery, detailed elsewhere [19,20]. Informed consent was obtained according to the Declaration of Helsinki (1991), and protocols and procedures were approved by Institutional Review Boards at each collection site. We used 720 plasma samples from the cohort: 262 AD, 199 MCI, and 259 CTL, selected based solely on availability of plasma samples. The replication cohorts comprised (1) 867 plasma samples (88 AD, 425 MCI, 349 CTL) from European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery (EMIF-AD MBD), a cross-European biomarker discovery cohort [21]; (2) 427 plasma samples (105 AD, 69 MCI, 253 CTL) from Maudsley Biomedical Research Centre Dementia Case Registry (DCR) [22]. In both cases, samples were selected based solely on availability of plasma; plasma was not collected from all individuals in the cohorts and stocks had been exhausted for others. Diagnostic categories were created using similar algorithms in the discovery and replication cohorts [19–22]. In all cohorts, the definition for CTL was a normal performance on neuropsychological assessment (within 1.5 SD of the average for age, gender, and education). Diagnosis of MCI was made according to the criteria of Petersen [23], and AD-type dementia was diagnosed using the National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association criteria [24].

Patient data available differed between the cohorts; therefore, a minimal clinical data set was collected and harmonized as described [21]; this data set comprised 1) demographics: age, gender, education; 2) clinical information: diagnosis, medication use, comorbidities, family history of dementia, functional impairment rating; 3) cognitive data: Mini–Mental State Examination, neuropsychological testing. Imaging data and CSF samples were not available for a majority of cases included in the cohorts and so could not be included in the analyses; however, this was not considered an issue given that the aim of the work was to identify plasma markers that correlated with clinical disease status.

2.2. Discovery phase assays

In the discovery phase, 53 plasma analytes were measured using commercial and in-house singleplex and multiplex assays on all available samples in duplicate from AddNeuroMed. Plasma clusterin, soluble complement receptor 2, C-reactive protein (CRP), colony-stimulating factor 1 (CSF1), and interleukin-23 (IL-23) were determined using commercially available enzyme-linked immunosorbent assays (clusterin, CRP, CSF1, and IL-23 from R&D systems (Abingdon, UK); cat# DY5874, DY1707, DY216, and DY5265 B) and soluble complement receptor 2 from Sino Biological (Beijing, China; cat# SEKA10811); protocols were as recommended by the manufacturers. Plasma soluble complement receptor 1 (sCR1), C1-inhibitor (C1inh), C5, C9, C1q, factor H-related protein 4 (FHR4), factor H (FH) Y402, and H402 variants were determined using optimized antibody pairs in in-house enzyme-linked immunosorbent assays (clusterin, CRP, CSF1, and IL-23 from R&D systems (Abingdon, UK); cat# DY5874, DY1707, DY216, and DY5265 B) and soluble complement receptor 2 from Sino Biological (Beijing, China; cat# SEKA10811); protocols were as recommended by the manufacturers. Plasma soluble complement receptor 1 (sCR1), C1-inhibitor (C1inh), C5, C9, C1q, factor H-related protein 4 (FHR4), factor H (FH) Y402, and H402 variants were determined using optimized antibody pairs in in-house enzyme-linked immunosorbent assays as described [25]. Ten complement biomarkers were measured using customized V-plex electrochemiluminescence (ECL) immunoassays (MSD; Rockville, Maryland); antibody pairs were developed and optimized in-house. Multiplex 1 comprised abundant analytes C3, C4, factor B (FB), FH, and factor I (FI). Multiplex 2 comprised low-concentration analytes factor D (FD); the activation fragments Bb, C3a, and iC3b; and the terminal complement complex (TCC). A calibration curve comprising five-fold dilutions of a mixture of protein standards was run in duplicate on each plate. ECL signal was measured on the Meso QuickPlex SQ 120 reader (MSD). Data acquisition and analysis was performed using MSD software Discovery workbench 4.0.
2.3. Replication phase assays

The analytes selected from the discovery phase for replication were sCR1, FB, FH, MCP-1, and eotaxin-1; FI, TCC, clusterin, and C4 were also included previously. V-plex chemokine panel 1 measures granulocyte-macrophage colony-stimulating factor, IL-1α, IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, and vascular endothelial growth factor–A in samples diluted 1:4; V-plex cytokine panel 1 measures interferon-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and tumor necrosis factor (TNF)-α in samples diluted 1:2 in proprietary buffer; V-plex cytokine panel 1 measures interferon-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and tumor necrosis factor (TNF)-α in samples diluted 1:2 in proprietary buffer; V-plex cytokine panel 1 measures interferon-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and tumor necrosis factor (TNF)-α in samples diluted 1:2 in proprietary buffer; V-plex cytokine panel 1 measures interferon-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and tumor necrosis factor (TNF)-α in samples diluted 1:2 in proprietary buffer; V-plex cytokine panel 1 measures interferon-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and tumor necrosis factor (TNF)-α in samples diluted 1:2 in proprietary buffer. All assays were performed according to manufacturer’s instructions using ECL detection as mentioned previously. Intra-assay and interassay limits for coefficients of variation (CV) were set at 25%, and data for samples with a CV above this were not included in the analysis.

2.3. Repli...
Table 1

Ten analytes associated with clinical state in the discovery phase

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Mean ± SD (AD n = 262)</th>
<th>Mean ± SD (MCI n = 199)</th>
<th>Mean ± SD (CTL n = 259)</th>
<th>P value AD vs. CTL</th>
<th>P value AD vs. MCI</th>
<th>P value MCI vs. CTL</th>
</tr>
</thead>
<tbody>
<tr>
<td>FH (µg/ml)</td>
<td>241.5 (56.4)</td>
<td>262.7 (71.8)</td>
<td>258.2 (73.0)</td>
<td>.01</td>
<td>ns</td>
<td>.004</td>
</tr>
<tr>
<td>F1 (µg/ml)</td>
<td>31.5 (7.0)</td>
<td>32.2 (6.9)</td>
<td>31.0 (7.5)</td>
<td>.049</td>
<td>ns</td>
<td>.03</td>
</tr>
<tr>
<td>sCR1 (ng/ml)</td>
<td>11.52 (3.03)</td>
<td>11.43 (3.10)</td>
<td>10.88 (3.01)</td>
<td>.043</td>
<td>.03</td>
<td>ns</td>
</tr>
<tr>
<td>C3 (µg/ml)</td>
<td>1042.7 (553.4)</td>
<td>1105.0 (377.4)</td>
<td>1004.2 (435.4)</td>
<td>&lt;.0001</td>
<td>ns</td>
<td>.001</td>
</tr>
<tr>
<td>C4 (µg/ml)</td>
<td>351.6 (129.6)</td>
<td>370.8 (136.2)</td>
<td>386.1 (159.3)</td>
<td>.01</td>
<td>.01</td>
<td>ns</td>
</tr>
<tr>
<td>C5 (µg/ml)</td>
<td>84.9 (16.2)</td>
<td>81.0 (14.7)</td>
<td>79.8 (14.7)</td>
<td>.001</td>
<td>.0004</td>
<td>ns</td>
</tr>
<tr>
<td>CRP (ng/ml)</td>
<td>996.8 (1145.6)</td>
<td>841.3 (711.1)</td>
<td>761.1 (810.5)</td>
<td>.007</td>
<td>.01</td>
<td>.09</td>
</tr>
<tr>
<td>MCP-1 (pg/ml)</td>
<td>63.1 (22.5)</td>
<td>68.5 (24.5)</td>
<td>63.0 (20.4)</td>
<td>.009</td>
<td>ns</td>
<td>.006</td>
</tr>
<tr>
<td>Eotaxin-1 (pg/ml)</td>
<td>141.6 (65.0)</td>
<td>143.3 (66.2)</td>
<td>162.5 (78.7)</td>
<td>&lt;.0001</td>
<td>&lt;.0001</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>MIP-1b (pg/ml)</td>
<td>58.9 (29.2)</td>
<td>58.1 (55.2)</td>
<td>63.1 (56.2)</td>
<td>.007</td>
<td>ns</td>
<td>.006</td>
</tr>
</tbody>
</table>

Abbreviations: AD, Alzheimer’s disease; CRP, C-reactive protein; CTL, control; KW, Kruskal-Wallis; MCI, mild cognitive impairment; ns, not significant; SD, standard deviation.

NOTE: Ten analytes showed statistically significant differences in concentration between clinical groups in the discovery phase. The table shows means and standard deviations, KW test P value, and Dunn test P values for each analyte.

3.2. Developing models to differentiate groups

3.2.1. AD from CTL

Stepwise selection demonstrated strong interdependence between some analytes and revealed other analytes that significantly and independently contributed to distinguishing clinical groups. SLR modeling was used to identify the most predictive set of analytes. A model combining FB, FH, sCR1, MCP-1, and eotaxin-1 with covariates age and APOe4 status best differentiated AD versus CTL. FH and eotaxin-1 were higher and FB, CR1, and MCP-1 were lower in AD compared to CTL. Diagnostic accuracy in distinguishing CTL from AD was moderate (AUC 0.71); 77% of samples were predicted correctly with 84% sensitivity and 70% specificity. In DCR, comprising 427 samples (105 AD, 69 MCI, 253 CTL), the model performed poorly (AD vs. CTL; AUC 0.56).

3.2.2. AD from MCI

A model combining sCR1, MCP-1, and eotaxin-1 with age and APOe4 optimally differentiated AD and MCI (AUC 0.74), correctly predicting 71% of samples with 75% sensitivity and 66% specificity (Fig. 2B; Table 2). FH and eotaxin-1 were higher and FB, sCR1, and MCP-1 were lower in AD compared to MCI samples. The model replicated in EMIF-AD MBD (AUC 0.67), correctly predicting 61% of samples with 71% sensitivity and 59% specificity. In DCR samples, the model performed poorly (AUC 0.56).

3.2.3. MCI from CTL

The optimal model to differentiate MCI from CTL comprised 15 analytes, each providing weak and independent predictive value. Smaller analyte sets were poor predictors (details not shown). We concluded that there was no reliable and practicable biomarker set from the analytes measured that distinguished MCI and CTL.

3.2.4. MCI progressors from nonprogressors

Baseline samples from 285 individuals with MCI who had either progressed to AD when reassessed 12 months later (progressors; 55) or had remained stable over this period (nonprogressors; 230) were compared in EMIF-AD MBD. Of the nine analytes measured, only two, FB (higher in progressors) and FH (lower in progressors), were significantly different between progressors and nonprogressors. A model combining these two analytes with age, the only significant covariable, was moderately predictive (AUC 0.71); 67% of samples correctly predicted, sensitivity 71%, specificity 67% (Table 3). In the 500 replications of stepwise models, age and FH were always selected and significant 499 times, FB was selected 414 times and significant 309 times. No other analyte was selected more than 67 times. The average AUC for the 500 replications was 0.69 (SD 0.09).

4. Discussion

A plasma biomarker or biomarker set that aids early diagnosis, stratification, prediction of disease course, or monitoring response to therapy in AD is a major unmet need. Numerous studies have sought plasma biomarkers relevant to AD, and many putative plasma protein biomarkers have been proposed (reviewed in the study by Baird et al. [28]); however, none has been robustly replicated. Currently, clinicians rely on neuropsychological testing, a time-consuming tool, to diagnose MCI and AD, with confirmation requiring either expensive neuroimaging (MRI or PET scanning) or invasive lumbar puncture to measure CSF markers of amyloid or tau pathology. These methods are not suitable either for high-volume screening of presymptomatic individuals,
required to identify early disease, or frequent monitoring required in assessing response to interventions. Biomarkers informative in CSF are currently difficult to measure in plasma in the routine context [29]. Recent technological advances have improved assay sensitivity, delivering ultrasensitive assays capable of measuring specific amyloid markers
Promising as these developments are, ultrasensitive assays require expensive purpose-built equipment beyond routine laboratory capacity and currently too costly for large-scale screening.

In this study, we set out to identify plasma analyte sets, measurable using simple multiplex enzyme-linked immunosorbent assay, that differentiated AD, MCI, and CTL groups. We took as a starting point the powerful multisource evidence that inflammation and complement dysregulation were important components of AD pathogenesis [13–17]. In the discovery phase, we used multiplex and singleplex immunoassays to measure 53 proteins relevant to inflammation and complement dysregulation in a large, well-validated cohort, and identify proteins and/or protein sets associated with AD and/or MCI clinical diagnosis. Ten of the 53 proteins were significantly different between groups of different clinical status; a heterogeneous group of analytes including three complement components (C3, C4, C5), two complement regulators (FH, FI), a soluble form of a complement receptor (sCR1), a classical marker of inflammation (CRP), and three chemokines (eotaxin-1, MCP-1, and MIP-1β). Stepwise selection demonstrated strong interdependence between some analytes, anticipated given that all were selected for relevance to complement and/or inflammation; however, several analytes significantly and independently contributed to distinguishing between clinical groups. To identify the most predictive set, models that tested all combinations of analytes and covariables were generated. The best model for AD versus CTL, including analytes sCR1, FB, FH, eotaxin-1, and MCP-1, with covariables age and APOE status, showed an AUC of 0.79 in the discovery cohort, considered “highly predictive” [32]. The best model for AD versus MCI, including analytes sCR1, eotaxin-1, and MCP-1 with covariables age and APOE status, yielded an AUC of 0.74, considered “moderately predictive” [32].

Both models were tested in two independent replication cohorts. In the larger of these, EMIF-AD MBD (comprising 867 samples: 88 AD, 425 MCI, 347 CTL), both models replicated, AD versus CTL strongly (AUC 0.81), and AD versus MCI moderately (AUC 0.67). In the smaller DCR cohort (105 AD, 69 MCI, 253 CTL), neither model replicated well (AUC 0.58 for AD vs. CTL; 0.56 for AD vs. MCI). The reasons for failure to replicate in the DCR cohort are unclear; however, this is a relatively small sample set, 60% of which are CTL samples. The strong replication of both models in the larger multicenter EMIF-AD MBD cohort provokes us to suggest that the analytes identified here, perhaps with other promising biomarkers, might provide a basis for a focused, relatively simple and inexpensive plasma multiplex test that could aid diagnosis. Further research in large, well-characterized cohorts to replicate, validate, and extend these findings is needed to deliver a reliable screening tool.

With the exception of FB, each of the analytes selected in the models has previously been associated with AD.

Fig. 2. Receiver operating characteristic (ROC) curves for models distinguishing clinical state or predicting progression. ROC curves were generated representing models which best differentiated AD from controls (A) or AD from MCI (B) in the discovery phase and predicted progression or nonprogression in the EMIF cohort (C). In each case, the area under the curve (AUC) for the selected model was calculated, and compared to that for the significant covariables alone, age + APOE ε4 in (A) and (B), age alone in (C). (A) Shows that a model including FB, FH, sCR1, MCP-1, and eotaxin-1, along with the covariables age and APOE genotype, differentiated AD and CTL with a predictive power (AUC) of 0.79 (red line), significantly better than the covariables alone (AUC 0.65; blue line). (B) Shows that a model including sCR1, MCP-1, and eotaxin-1, along with the covariables age and APOE genotype, differentiated AD and MCI with AUC of 0.74 (red line), significantly better than the covariables alone (AUC 0.63; blue line). (C) Shows that a model including FB and FH along with age as covariable differentiated MCI progressors and nonprogressors with AUC of 0.71 (red line). The predictive power was significantly greater than that obtained using the covariable alone (AUC 0.66; blue line). Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CTL, control; MCI, mild cognitive impairment.
Table 2
Multivariate models for distinguishing between diagnostic groups

<table>
<thead>
<tr>
<th>Predictor</th>
<th>AD vs. CTL</th>
<th>P value</th>
<th>AD vs. MCI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>−13.49 (−27.16; 0.17)</td>
<td>.05</td>
<td>−3.62 (−7.89; 0.65)</td>
<td>.10</td>
</tr>
<tr>
<td>Age</td>
<td>0.07 (0.04; 0.12)</td>
<td>.00005</td>
<td>0.06 (0.02; 0.10)</td>
<td>.002</td>
</tr>
<tr>
<td>1 APOE e4</td>
<td>0.74 (0.22; 1.25)</td>
<td>.005</td>
<td>0.41 (−0.10; 0.92)</td>
<td>.12</td>
</tr>
<tr>
<td>2 APOE e4</td>
<td>2.03 (1.0; 3.05)</td>
<td>.0001</td>
<td>1.99 (0.86; 3.13)</td>
<td>.0006</td>
</tr>
<tr>
<td>Eotaxin-1</td>
<td>1.56 (0.78; 2.35)</td>
<td>.00009</td>
<td>1.74 (0.97; 2.52)</td>
<td>.00001</td>
</tr>
<tr>
<td>MCP-1</td>
<td>−1.31 (−2.21; 0.40)</td>
<td>.0005</td>
<td>−1.91 (−2.82; −1.01)</td>
<td>.00003</td>
</tr>
<tr>
<td>sCR1</td>
<td>−0.90 (−1.85; 0.06)</td>
<td>.067</td>
<td>−1.36 (−2.30; −0.41)</td>
<td>.005</td>
</tr>
<tr>
<td>FH</td>
<td>2.85 (1.42; 4.27)</td>
<td>.00009</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>FB</td>
<td>−2.33 (−3.60; −1.06)</td>
<td>.0003</td>
<td>n/a</td>
<td>n/a</td>
</tr>
</tbody>
</table>

Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CTL, control; MCI, mild cognitive impairment; logOR (95% CI), log odds ratio of the predictor and their 95% confidence interval; Intercept, log odds ratio if the predictors are equal to 0; 1 APOE E4/2 APOE E4: log odds ratio of possessing 1 or 2 e4 alleles compared to possessing no e4 allele; n/a, predictors not included in the given model.

NOTE. The table summarizes the selected logistic regression models derived from the AddNeuroMed discovery cohort, AD versus CTL in the left panel, AD versus MCI in the right panel.

sCR1 (reduced in AD vs. CTL and MCI) had not been measured in AD plasma previously but was reported higher in CSF in AD versus CTL [33]. FH (increased in AD vs. CTL) was reported higher in AD plasma in several studies [4,34,35], although some reported no difference between clinical groups [36]. Eotaxin-1 (higher in AD plasma vs. CTL and MCI) and MCP-1 (lower in AD plasma vs. CTL and MCI), both C–C chemokine family members, were reported as plasma markers of AD status in several studies [37–42]; elevated MCP-1 and eotaxin-1 correlated with greater memory impairment in MCI/AD [43].

Several studies have reported plasma biomarkers predictive of MCI progression to AD. An 18-analyte biomarker signature dominated by cytokines/chemokines predicted progression within 5 years with 81% accuracy [44]. A 60-analyte set was predictive of MCI progression to AD with 79% accuracy [45], and a 10-analyte panel, including complement and inflammatory proteins, predicted MCI progression to AD with 87% accuracy [22]. Our published study identified a model comprising three analytes, FI, TCC, and clusterin that, with APOE 4 status, predicted progression (AUC 0.86) [26]. To date, none of these findings have been independently replicated. Of the cohorts available to us, only EMIF-AD MBD included data on progression of MCI cases to AD; 19% of informative MCI cases had progressed to AD a year after sampling. Of the 10 analytes measured, two were significantly different; FB levels were higher and FH lower in MCI progressors versus nonprogressors. These two biomarkers together with age (the only significant covariable) predicted MCI conversion with AUC 0.71. Notably, FB is a key enzyme in the complement amplification loop while FH is the critical loop regulator; increased FB and decreased FH seen in progressors would favor amplification, suggesting that amplification loop dysregulation might predispose to progression. We were unable to replicate this finding in other cohorts as data on conversion were not available. Although the model reported for predicting MCI conversion differs from our previous report [26], both identified markers of complement activation/regulation, implying that complement dysregulation is a critical predictor of progression. This finding resonates with preclinical data suggesting that complement and microglial activation play important roles as mediators of neurotoxicity in AD [46]. Further research to replicate and validate markers of complement dysregulation as predictors of progression is required.

There are limitations to the present study. The cohorts were collected across a wide range of centers and without stringent attention to sampling, separation, and storage protocols that are important for complement and other immunity assays; however, despite this suboptimal aspect, characteristic of real-world sample collections, strongly predictive marker sets emerged, increasing the likelihood of utility in clinical practice. For several analytes, the commercial cytokine/chemokine platform was insufficiently sensitive for detection in plasma, highlighting the need for better assays. For most subjects in the cohorts analyzed, imaging data and/or CSF samples were not available and thus could not be included in the analysis. Despite these limitations, we
discovered and replicated evidence that neuroinflammation and complement dysregulation are pathological drivers in AD and thus potential therapeutic targets. Several observational studies have reported that long-term use of nonsteroidal anti-inflammatory drugs is associated with reduced risk of dementia [47,48]; however, randomized controlled trials and systematic reviews found little or no benefit of nonsteroidal anti-inflammatory drugs [49,50]. Perhaps, interventions in these latter studies were commenced too late to confer benefit. Inflammatory biomarkers to stratify and select patients for targeted early intervention might benefit future trials of anti-inflammatory interventions. Targeting complement dysregulation is, as yet, untested in AD. Although current anticompement drugs are tailored to preclinical or early MCI patients identified and selected using markers of complement dysregulation may offer a new pathway to prevention of AD [52].

Acknowledgments

This publication incorporates results from the research project entitled “Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer’s Disease” which is funded by a grant from the Wellcome Trust (grant number: 104025/Z/14/Z). A complete list of Consortium members is given in the Annex. The AddNeuroMed and DCR plasma samples were provided by the NIHR Biomedical Research Centre and NIHR Dementia Biomedical Research Unit hosted at Kings College London and South London and Maudsley NHS Foundation Trust and funded by the National Institute for Health Research under its Biomedical Research Centers initiative. Authors’ contributions: B.P.M., S.L., A.R.M., S.T., and A.J.N.-H. contributed to study design. A.R.M., C.L., and C.O.’H. processed samples and conducted all assays. S.T. and A.J.N.-H. conducted data processing and statistical analyses. B.P.M., A.R.M., S.L., and S.T. contributed to the writing of the paper. Other authors contributed to the EMMF-AD MBD cohort. All authors read and approved the final manuscript. Annex: NIMA—Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer’s Disease. Consortium members—Part 1: Cambridge: Edward T. Bullmore (MD, PI, EC)1,2,11, Junaid Bhatti1, Samuel J. Chamberlain1,2, Marta M. Correia1,2, Anna L. Crofts1, Amber Dickinson*, Andrew C. Foster*, Manfred G. Kitzbichler1, Clare Knight*, Mary-Ellen Lyall1, Christina Maurice1, Ciara O’Donnell1, Linda J. Pinto1, Peter St George Hyslop1,13,14, Lorinda Turner1, Petra Vertes1, Barry Widmer1, Guy B. Williams1,2,3,4, MagneWinnefeld1,2,3,4, Martin Willnow1,2,3,4, Wendy Willenbrock1,2,3,4, Martin Wierenga1,2,3,4, Karen Worth1,2,3,4, John White1,2,3,4, Mark White1,2,3,4, Paul Whittal1,2,3,4, Richard Wootton1,2,3,4, James Wykes1,2,3,4, David Yang1,2,3,4, Jan Ysselsteyn1,2,3,4, Susan Zandbelt1,2,3,4. Kings College London: Carmine M. Pariante (PI)10, Federico Turkheimer (PI)2, Gareth J. Barker20, Heidi Byrom10, Diana Cash20, Annamaria Cattaneo10, Antony Gec20, Caitlin Hastings10, Nicole Mariani10, Anna McLaughlin10, Valeria Mondelli10, Maria Nettis10, Naghmeh Nikheslat10, Karen Randall20, Hannah Sheridan*, Camilla Simmonds20, Nisha Singh20, Victoria Van Loo*, Marta Vicente-Rodriguez20, Tobias C. Wood20, Courtney Worrell*, Zuzanna Zajkowska.* Lundbeck: Niels Plath (EC)20, Jan Egebjerg21, Hans Eriksson21, Francois Gastambide21, Karen Husted Adams21, Ross Jeggo21, Christian Thomsen21, Ian Torleif Pedersen21, Brian Campbell*, Thomas Möller*, Bob Nelson*, Stevin Zom.*


Southampton: V. Hugh Perry (PI)27, Madeleine Cleal*, Gemma Fryatt27, Diego Gomez-Nicola27, Renzo Mancuso12, Richard Reynolds.27


University of Toronto (sub-contracted to Cambridge): Howard Mount.13

MD = mood disorders workpackages lead; AD = Alzheimer’s disease workpackages lead; PI = principal investigator; EC = executive committee member.

1 Department of Psychiatry, School of Clinical Medicine, University of Cambridge, CB2 0SZ, UK.

2 Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, CB21 5EF, UK.

3 Sackler Centre, Institute of Health & Wellbeing, University of Glasgow, Sir Graeme Davies Building, Glasgow, G12 8TA, UK.

4 Neuroscience, Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340, Beerse, Belgium.

5 The Maurice Wohl Clinical Neuroscience Institute, Cutcombe Road, London, SE5 9RT, UK.
RESEARCH IN CONTEXT

1. Systematic review: The authors reviewed the current literature using traditional (e.g., Google Scholar; PubMed) sources to identify published studies utilizing inflammation-relevant plasma biomarkers, in particular complement markers, for diagnosis, staging, or risk prediction of Alzheimer’s disease. They noted the dearth of replicated plasma biomarkers and small sample size in many published studies.

2. Interpretation: Our findings identify sets of inflammatory biomarkers in plasma that distinguish clinical subgroups (controls: mild cognitive impairment; Alzheimer’s disease) in a large multicenter cohort; these replicate in an independent cohort. Markers predictive of progression were also identified in the latter cohort.

3. Future directions: The findings require further replication in additional and larger independent cohorts, before development as a clinically viable multiplexed test for diagnosis and patient stratification.

References


